Hepatitis C virus quasispecies in chronically infected children subjected to interferon-ribavirin therapy

Archives of Virology

Volumn 155, Issue 12, 2010, Pages 1977-1987

  Figlerowicz, Magdalena ^b   Jackowiak, Paulina ^a   Formanowicz, Piotr ^a,c   Kedziora, Paweł ^c   Alejska, Magdalena ^a   Malinowska, Nelli ^a   Błazewicz, Jacek ^a,c   Figlerowicz, Marek ^a  

^a INSTITUTE OF BIOORGANIC CHEMISTRY   (Poland)

^b POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^c POZNAN UNIVERSITY OF TECHNOLOGY   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; ANTIVIRUS AGENT; E1 PROTEIN, HEPATITIS C VIRUS; GLYCOPROTEIN E2, HEPATITIS C VIRUS; RIBAVIRIN; VIRUS DNA; VIRUS ENVELOPE PROTEIN;

ADOLESCENT; ARTICLE; CHEMISTRY; CHILD; CLASSIFICATION; CLUSTER ANALYSIS; DNA SEQUENCE; FEMALE; GENETIC POLYMORPHISM; GENETICS; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; ISOLATION AND PURIFICATION; MALE; SEQUENCE HOMOLOGY; VIROLOGY;

ADOLESCENT; ANTIVIRAL AGENTS; CHILD; CLUSTER ANALYSIS; DNA, VIRAL; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2B; MALE; POLYMORPHISM, GENETIC; RIBAVIRIN; SEQUENCE ANALYSIS, DNA; SEQUENCE HOMOLOGY; VIRAL ENVELOPE PROTEINS;

HEPATITIS C VIRUS;

EID: 78449305271     PISSN: 03048608     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00705-010-0789-7     Document Type: Article

References (30)

1. Alberti A, Benvegnu L (2003) Management of hepatitis C. J Hepatol 38(Suppl 1): 104-118.
2. Canobio S, Guilbert CM, Troesch M, Samson J, Lemay M, Pelletier VA, Bernard-Bonnin AC, Kozielski R, Lapointe N, Martin SR, Soudeyns H (2004) Differing patterns of liver disease progression and hepatitis C virus (HCV) quasispecies evolution in children vertically coinfected with HCV and human immunodeficiency virus type 1. J Clin Microbiol 42: 4365-4369.
3. Domingo E, Escarmis C, Sevilla N, Moya A, Elena SF, Quer J, Novella IS, Holland JJ (1996) Basic concepts in RNA virus evolution. Faseb J 10: 859-864.
4. Domingo E, Escarmis C, Lazaro E, Manrubia SC (2005) Quasispecies dynamics and RNA virus extinction. Virus Res 107: 129-139.
5. Farci P, Strazzera R, Alter HJ, Farci S, Degioannis D, Coiana A, Peddis G, Usai F, Serra G, Chessa L, Diaz G, Balestrieri A, Purcell RH (2002) Early changes in hepatitis C viral quasispecies during interferon therapy predict the therapeutic outcome. Proc Natl Acad Sci USA 99: 3081-3086.
6. Farci P, Quinti I, Farci S, Alter HJ, Strazzera R, Palomba E, Coiana A, Cao D, Casadei AM, Ledda R, Iorio R, Vegnente A, Diaz G, Tovo PA (2006) Evolution of hepatitis C viral quasispecies and hepatic injury in perinatally infected children followed prospectively. Proc Natl Acad Sci USA 103: 8475-8480.
7. Ferenci P (2004) Predictors of response to therapy for chronic hepatitis C. Semin Liver Dis 24(Suppl 2): 25-31.
8. Figlerowicz M, Alejska M, Kurzyńska-Kokorniak A, Figlerowicz M (2003) Genetic variability: the key problem in the prevention and therapy of RNA-based virus infections. Med Res Rev 23: 488-518.
9. Figlerowicz M, Służewski W, Kowala-Piaskowska A, Mozer-Lisewska I (2004) Interferon alpha and ribavirin in the treatment of children with chronic hepatitis C. Eur J Pediatr 163: 265-267.
10. Gaud U, Langer B, Petropoulou T, Thomas HC, Karayiannis P (2003) Changes in hypervariable region 1 of the envelope 2 glycoprotein of hepatitis C virus in children and adults with humoral immune defects. J Med Virol 69: 350-356.
11. Gerlach TJ, Zachoval R, Gruener N, Jung M-C, Ulsenheimer A, Schraut W, Schirren A, Waechtler M, Backmund M, Diepolder HGP (2001) Acute hepatitis C: natural course and response to antiviral treatment. Hepatology 34: A341.
12. Gerotto M, Resti M, Dal Pero F, Migliorato I, Alberti A, Bortolotti F (2006) Evolution of hepatitis C virus quasispecies in children with chronic hepatitis C. Infection 34: 62-65.
13. Gismondi MI, Becker PD, Diaz Carrasco JM, Guzman CA, Campos RH, Preciado MV (2009) Evolution of hepatitis C virus hypervariable region 1 in immunocompetent children born to HCV-infected mothers. J Viral Hepat 16: 332-339.
14. Hadziyannis S, Cheinquer JH, Morgan T, Diago M, Jensen DM, Sette H Jr, Ramadori G (2002) Peginterferon alfa-2a (40kD) (PEGASYS) in combination with ribavirin (RBV): efficacy and safety results from a phase III, randomised, double-blind multicentre study examining effect of duration of treatment and RBV dose. J Hepatol 36(Supp 1): 3.
15. Jonas MM (2002) Children with hepatitis C. Hepatology 36: S173-S178.
16. Kuiken C, Yusim K, Boykin L, Richardson R (2005) The Los Alamos hepatitis C sequence database. Bioinformatics 21: 379-384.
17. Kumar S, Nei M, Dudley J, Tamura K (2008) MEGA: a biologist-centric software for evolutionary analysis of DNA and protein sequences. Brief Bioinform 9: 299-306.
18. McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, Goodman ZD, Ling MH, Cort S, Albrecht JK (1998) Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 339: 1485-1492.
19. Mizokami M, Ohno T (1998) Determination of HCV quasispecies by cloning and sequencing. In: Lau JYN (ed) Hepatitis C protocols. Humana Press, New Jersey, USA, pp 207-211.
20. Moreau I, Levis J, Crosbie O, Kenny-Walsh E, Fanning LJ (2008) Correlation between pre-treatment quasispecies complexity and treatment outcome in chronic HCV genotype 3a. Virol J 5: 78.
21. Pawlotsky JM, Pellerin M, Bouvier M, Roudot-Thoraval F, Germanidis G, Bastie A, Darthuy F, Remire J, Soussy CJ, Dhumeaux D (1998) Genetic complexity of the hypervariable region 1 (HVR1) of hepatitis C virus (HCV): influence on the characteristics of the infection and responses to interferon alfa therapy in patients with chronic hepatitis C. J Med Virol 54: 256-264.
22. Penin F, Combet C, Germanidis G, Frainais PO, Deleage G, Pawlotsky JM (2001) Conservation of the conformation and positive charges of hepatitis C virus E2 envelope glycoprotein hypervariable region 1 points to a role in cell attachment. J Virol 75: 5703-5710.
23. Pond SL, Frost SD (2005) Datamonkey: rapid detection of selective pressure on individual sites of codon alignments. Bioinformatics 21: 2531-2533.
24. Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, Bain V, Heathcote J, Zeuzem S, Trepo C, Albrecht J (1998) Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. international hepatitis interventional therapy group (IHIT). Lancet 352: 1426-1432.
25. Puig-Basagoiti F, Forns X, Furcic I, Ampurdanes S, Gimenez-Barcons M, Franco S, Sanchez-Tapias JM, Saiz JC (2005) Dynamics of hepatitis C virus NS5A quasispecies during interferon and ribavirin therapy in responder and non-responder patients with genotype 1b chronic hepatitis C. J Gen Virol 86: 1067-1075.
26. Quesnel-Vallieres M, Lemay M, Lapointe N, Martin SR, Soudeyns H (2008) HCV quasispecies evolution during treatment with interferon alfa-2b and ribavirin in two children coinfected with HCV and HIV-1. J Clin Virol 43: 236-240.
27. Simmonds P (2004) Genetic diversity and evolution of hepatitis C virus-15 years on. J Gen Virol 85: 3173-3188.
28. Tamura K, Dudley J, Nei M, Kumar S (2007) MEGA4: molecular evolutionary genetics analysis (MEGA) software version 4. 0. Mol Biol Evol 24: 1596-1599.
29. Toyoda H, Kumada T, Nakano S, Takeda I, Sugiyama K, Osada T, Kiriyama S, Sone Y, Kinoshita M, Hadama T (1997) Quasispecies nature of hepatitis C virus and response to alpha interferon: significance as a predictor of direct response to interferon. J Hepatol 26: 6-13.
30. Ueda E, Enomoto N, Sakamoto N, Hamano K, Sato C, Izumi N, Watanabe M (2004) Changes of HCV quasispecies during combination therapy with interferon and ribavirin. Hepatol Res 29: 89-96.